{"result": {"id": "c00f3d7f-d8bf-458f-9b22-2373c7440a36", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>SPC<|>ORGANIZATION<|>SPC is a combination drug with both antihypertensive and lipid-lowering effects, suitable for most patients with hypertension and hypercholesterolemia)\n##\n(\"entity\"<|>ASTEROID<|>EVENT<|>ASTEROID is a research study that showed rosuvastatin treatment could reduce atherosclerotic plaque volume by 0.79%, fundamentally preventing cardiovascular events)\n##\n(\"entity\"<|>瑞舒伐他汀<|>PERSON<|>Rosuvastatin is a statin drug used in the ASTEROID study to treat atherosclerosis)\n##\n(\"entity\"<|>PCSK9<|>ORGANIZATION<|>PCSK9 is a proprotein convertase subtilisin/kexin type 9 inhibitor used for treating extremely high-risk ASCVD patients who cannot tolerate other lipid-lowering drugs)\n##\n(\"entity\"<|>依折麦布<|>PERSON<|>Ezetimibe is a lipid-lowering drug that can be used alone or in combination with low-dose statins or Xuezhikang for patients who cannot tolerate standard treatments)\n##\n(\"relationship\"<|>SPC<|>瑞舒伐他汀<|>SPC and rosuvastatin are both used for lipid-lowering and cardiovascular protection<|>6)\n##\n(\"relationship\"<|>ASTEROID<|>瑞舒伐他汀<|>The ASTEROID study used rosuvastatin to demonstrate its effectiveness in reducing atherosclerotic plaque<|>8)\n##\n(\"relationship\"<|>PCSK9<|>依折麦布<|>PCSK9 inhibitors and ezetimibe are alternative treatments for patients who cannot tolerate statins<|>5)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752165657, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 389, "prompt_tokens": 2415, "total_tokens": 2804, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 623}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 固醇吸收抑制剂以及同时具有降压和降胆固 醇作用的 SPC［14］。强化调脂治疗不仅可以改善动 脉的顺应性，还可以有效降低动脉压［35］。他汀类 调脂药物对高血压患者心血管重建有一定的影响， \tASTEROID 研究结果显示［36］，瑞舒伐他汀治疗 能使整个目标血管的粥样硬化瘤体积缩小 0.79%  （P<0.001），提示可以从根本上预防心血管事件 的发生。\n　　（3）注意联合治疗个体化药物选择的问题：具 有降压和调血脂作用的 SPC 适用于大多数高血压 伴高胆固醇血症患者的调脂治疗，并可以使大多数 患者 LDL-C 达标。SPC 可以减少给药数量，提高 长期治疗的依从性。给药后根据患者情况，必要时 联合其他降压或调脂药物以获得血压、血脂双重达 标［37-39］。初始给药后 4~6 周应复查血脂谱、肝功\n\n\n　能和肌酸激酶。氨基转移酶超过正常上限3倍或肌 酸激酶超过正常上限 5 倍应暂停使用调脂药物；治 疗后出现肌肉症状（肌无力、肌痛）者也需暂时停 药。待生化指标恢复正常、肌肉症状消失后，可酌 情尝试低剂量他汀类药物或血脂康联合依折麦布， 或单用依折麦布治疗，仍不能耐受或无效的极高危 \t\tASCVD 患者应考虑采用前蛋白转化酶枯草溶菌素 9 （proprotein convertase subtilisin/kexin type 9， \tPCSK9）抑制剂治疗。\n4.4 中医治疗\n4.4.1 高血压和血脂异常的病机\n　　高血压和血脂异常在中医属于“眩晕”“痰浊” 的范畴，与机体内的肝、肾、脾三脏功能失调存在   密切关联。高血压与血脂异常者，多责之于脾。高   血压以眩晕为主要症状，而痰浊阻塞会进一步加重   眩晕之症。脾的功能失常会影响肝肾之功，肝肾不   足亦会影响脾，三者互相影响，互为发病，而致本病。  中医认为其病因以肝肾阴亏，脾肾气虚，痰瘀互结   为主，对其治疗应以平肝、化痰及健脾原则为主［40］。\n4.4.2 中医辨证论治\n　　中医秉承整体观念，将血压与血脂异常都归纳 为“证”的因素，进行统一治疗。辨证理论指导下 的中医药治疗常能异病同治，降低血压的同时调节 血脂，可缓解不适症状（表 3 和表 4）。\n　　中医强调从整体观念出发进行辨证论治。高血 压合并血脂异常多以补肝肾、祛�\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_5d5ff2b437453dcc9877d8cce76085a4f1f242c46c3cb08b95f706f3944e1ce7_v2"}